The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well.
The treatment method, called Photodynamic Treatment (PDT), means that the patient is given a light-activated drug that accumulates in the tumor. When the cancer tissue is illuminated using SpectraCures instruments, the medicine is activated and the tumour is eliminated.
The target group of the study is patients who received relapse of high-risk prostate cancer after having radiotherapy. For this patient group, routine, curative treatment options are lacking and they are normally referred to hormone therapy to inhibit tumor growth. Hormonal treatment often causes extensive undesirable side effects. SpectraCure aims to offer a curative treatment option for these patients, with fewer and less severe side effects.
At the treatment, Dr Keith Cengel, who is the responsible physician for the clinical study in Philadelphia, was also involved. After the treatment, Cengel commented: "SpectraCures treatment system can be the Thing! This can really be the Thing that gets done on a regular basis."
